• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022.马来西亚改善癌症药物可及性的挑战与策略:2022年第二届马来西亚癌症研究学会国际科学会议上表达的观点综述
Cancer Manag Res. 2023 Aug 21;15:851-862. doi: 10.2147/CMAR.S420890. eCollection 2023.
2
Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.马来西亚的药品可及性和可负担性:需要国家定价政策。
Appl Health Econ Health Policy. 2019 Oct;17(5):641-654. doi: 10.1007/s40258-019-00480-9.
3
Joint 24th Medicines for Europe and 21st International Generic and Biosimilars Association (IGBA) Annual Conference (June 13-15, 2018 - Budapest, Hungary).欧洲药品协会与第21届国际仿制药和生物类似药协会(IGBA)联合年会(2018年6月13日至15日——匈牙利布达佩斯)。
Drugs Today (Barc). 2018 Aug;54(8):499-505. doi: 10.1358/dot.2018.54.8.2866119.
4
"What's up with price controls?" Stakeholders' views on the regulation of pharmaceutical pricing in Malaysia.“价格管制是怎么回事?”马来西亚药品定价监管的利益相关者观点。
PLoS One. 2023 Dec 7;18(12):e0291031. doi: 10.1371/journal.pone.0291031. eCollection 2023.
5
Contracting retail pharmacies as a source of essential medicines for public sector clients in low- and middle-income countries: a scoping review of key considerations, challenges, and opportunities.在低收入和中等收入国家,将零售药店作为公共部门客户基本药物的来源:对关键考虑因素、挑战和机遇的范围界定审查
J Pharm Policy Pract. 2023 May 2;16(1):60. doi: 10.1186/s40545-023-00557-w.
6
Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.巴基斯坦当地制药行业实施和遵守国际公认质量标准的体制障碍和促进因素:一项定性研究。
Health Policy Plan. 2019 Jul 1;34(6):440-449. doi: 10.1093/heapol/czz054.
7
Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference.危机中的药品政策?PPRI会议确定的挑战与解决方案
J Pharm Policy Pract. 2016 Mar 15;9:9. doi: 10.1186/s40545-016-0056-8. eCollection 2016.
8
Access to cancer medication in public hospitals in a middle-income country: The view of stakeholder.中等收入国家公立医院的癌症药物获取情况:利益相关者的观点
Res Social Adm Pharm. 2020 Sep;16(9):1255-1263. doi: 10.1016/j.sapharm.2019.11.015. Epub 2019 Nov 27.
9
Innovations in pharmaceutical policies and learnings for sustainable access to affordable medicines.制药政策创新与可持续获取平价药品的经验教训。
J Pharm Policy Pract. 2024 Apr 24;17(Suppl 1):2335492. doi: 10.1080/20523211.2024.2335492. eCollection 2024.
10
Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.亚太地区医疗技术的循证决策:来自印度、马来西亚、菲律宾和巴基斯坦的经验。
Value Health. 2009 Nov-Dec;12 Suppl 3:S18-25. doi: 10.1111/j.1524-4733.2009.00622.x.

引用本文的文献

1
Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil.第一届肿瘤学峰会会议记录:拉丁美洲分会,2023年5月19日至20日,巴西里约热内卢
Cancers (Basel). 2024 Sep 3;16(17):3063. doi: 10.3390/cancers16173063.
2
Systemic Barriers to Optimal Cancer Care in Resource-Limited Countries: Jordanian Healthcare as an Example.资源有限国家优化癌症护理的系统性障碍:以约旦医疗保健为例。
Cancers (Basel). 2024 Mar 11;16(6):1117. doi: 10.3390/cancers16061117.
3
Immune modulation and prognostic significance of MCM10 in pan-cancer: a comprehensive analysis.MCM10在泛癌中的免疫调节及预后意义:一项综合分析
Am J Transl Res. 2023 Nov 15;15(11):6451-6463. eCollection 2023.

本文引用的文献

1
Artificial intelligence and real-world data for drug and food safety - A regulatory science perspective.人工智能和真实世界数据在药物和食品安全监管中的应用——监管科学视角。
Regul Toxicol Pharmacol. 2023 May;140:105388. doi: 10.1016/j.yrtph.2023.105388. Epub 2023 Apr 13.
2
Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries.支持 ICH 成员国加快药物开发和审批的监管途径。
Ther Innov Regul Sci. 2023 May;57(3):484-514. doi: 10.1007/s43441-022-00480-3. Epub 2022 Dec 3.
3
Barriers in access to oncology drugs - a global crisis.癌症药物获取障碍——全球危机。
Nat Rev Clin Oncol. 2023 Jan;20(1):7-15. doi: 10.1038/s41571-022-00700-7. Epub 2022 Nov 15.
4
The Burden of Out-of-Pocket Expenditure Related to Gynaecological Cancer in Malaysia.马来西亚与妇科癌症相关的自付费用负担
Healthcare (Basel). 2022 Oct 20;10(10):2099. doi: 10.3390/healthcare10102099.
5
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.头颈部癌的低剂量免疫疗法:一项随机研究。
J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20.
6
A Socio-Ecological Framework for Cancer Prevention in Low and Middle-Income Countries.社会生态框架在中低收入国家的癌症预防中的应用。
Front Public Health. 2022 May 26;10:884678. doi: 10.3389/fpubh.2022.884678. eCollection 2022.
7
Programmed death-ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non-small-cell lung cancer in a resource-limited country.程序性死亡配体 1 表达与免疫检查点抑制剂在资源有限国家晚期非小细胞肺癌患者中的应用。
Thorac Cancer. 2022 Jun;13(11):1676-1683. doi: 10.1111/1759-7714.14442. Epub 2022 May 3.
8
Priorities for cancer research in low- and middle-income countries: a global perspective.中低收入国家癌症研究重点:全球视角。
Nat Med. 2022 Apr;28(4):649-657. doi: 10.1038/s41591-022-01738-x. Epub 2022 Apr 19.
9
Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia.沙特阿拉伯的药品本地化生产及其对药品安全的影响。
Saudi Pharm J. 2022 Jan;30(1):28-38. doi: 10.1016/j.jsps.2021.12.002. Epub 2021 Dec 20.
10
A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer.帕博利珠单抗单剂治疗导致肺癌产生深远且持久的应答。
Thorac Cancer. 2022 Feb;13(4):648-652. doi: 10.1111/1759-7714.14314. Epub 2022 Jan 12.

马来西亚改善癌症药物可及性的挑战与策略:2022年第二届马来西亚癌症研究学会国际科学会议上表达的观点综述

Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022.

作者信息

Tan Shing Cheng, Poh Wen Tsin, Yong Audrey Chee Hui, Chua Eng Wee, Ooi Der Jiun, Mahmud Rozi, Thiagarajan Muthukkumaran, Stanslas Johnson

机构信息

UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.

Pharmacotherapeutic Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.

出版信息

Cancer Manag Res. 2023 Aug 21;15:851-862. doi: 10.2147/CMAR.S420890. eCollection 2023.

DOI:10.2147/CMAR.S420890
PMID:37636030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10457461/
Abstract

Considerable progress has been made in cancer drug development in recent decades. However, for people in low- and middle-income countries, including Malaysia, many of these drugs are not readily available. During the 2nd Malaysian Association for Cancer Research (MACR) International Scientific Conference, a forum discussion was held to address these challenges and explore strategies to improve access to cancer medicines in the country. This paper presents the results of the said forum discussion. A few challenges to cancer drug access were highlighted, including lengthy approval and regulatory practices, cost of medicines, and manufacturing barriers. Besides, a few strategies for mitigating some of these challenges were proposed, such as mechanisms for cost reduction, uptake of biosimilars and generics, local manufacturing, public-private partnerships, strengthening the role of insurance companies, funding and regulation, and advocacy for fair pricing, by drawing examples from cancer medicines access initiatives in Malaysia and initiatives for different disease groups. Overall, this paper provides a comprehensive overview of the challenges and strategies for improving access to cancer medicines in Malaysia and provides valuable insights for policymakers, healthcare providers, the pharmaceutical industry, cancer patients, cancer support groups, and other stakeholders working on this important issue.

摘要

近几十年来,癌症药物研发取得了长足进展。然而,对于包括马来西亚在内的低收入和中等收入国家的人们来说,许多此类药物难以获取。在第二届马来西亚癌症研究协会(MACR)国际科学会议期间,举行了一场论坛讨论,以应对这些挑战,并探索改善该国癌症药物可及性的策略。本文介绍了上述论坛讨论的结果。会上强调了癌症药物可及性面临的一些挑战,包括冗长的审批和监管程序、药品成本以及生产障碍。此外,还提出了一些应对其中一些挑战的策略,例如成本降低机制、生物类似药和仿制药的采用、本地生产、公私伙伴关系、加强保险公司的作用、资金与监管,以及通过列举马来西亚癌症药物可及性举措和针对不同疾病群体的举措来倡导公平定价。总体而言,本文全面概述了马来西亚改善癌症药物可及性的挑战与策略,并为政策制定者、医疗服务提供者、制药行业、癌症患者、癌症支持团体以及致力于这一重要问题的其他利益相关者提供了宝贵见解。